Peritoneal Serous Carcinoma

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
FDA (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
EMA (1) FDA (2)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (2)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (2)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (2)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (1)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
FDA (1)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
EMA (1) FDA (1)	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine